Two Alzheimer’s medicine had been hailed as therapies that may remodel care. Why are barely any UK sufferers getting them?
Well being editor Hanna has seemed on the newest developments in dementia medicine. (Picture: Categorical/Getty)
On September 29, 2022, consultants hailed “a historic second for dementia analysis” when the world welcomed a long-awaited drug breakthrough. A trial had definitively confirmed for the primary time {that a} drugs each cleared poisonous amyloid protein from the brains of Alzheimer’s sufferers and considerably delayed development of signs. It felt like a watershed second within the battle in opposition to some of the feared ailments of outdated age. Nonetheless, as we speak — 1,290 days later — virtually no UK sufferers are capable of entry the remedy.
So what went unsuitable and what may occur subsequent? The Categorical has taken a have a look at the most recent dementia drug developments. The trial outcomes that despatched ripples of pleasure by analysis circles had been for lecanemab, a drug developed by Tokyo-based Eisai and US agency Biogen. The information confirmed it slowed cognitive decline by 27% over 18 months, described as a “modest however clear” profit.
We use your sign-up to supply content material in methods you have consented to and to enhance our understanding of you. This may occasionally embody adverts from us and third events based mostly on our understanding. You possibly can unsubscribe at any time. Learn our Privateness Coverage
Learn extra: This simple every day behavior could lower dementia danger by 15%
One skilled declared: “God is aware of, we have waited lengthy sufficient for this.” One other stated that whereas the drug was not a treatment, it heralded “a change in outlook for folks with the primary indicators of Alzheimer’s illness”.
However within the months that adopted, a debate emerged about simply how modest these outcomes had been. What does a 27% slowing truly imply for your beloved who’s within the early levels of Alzheimer’s?
Some consultants started to argue that the drug’s advantages had been too small to be noticeable in a real-world setting, exterior of a scientific trial the place probably the most refined adjustments will be measured.
In the meantime, there have been uncommon however severe unintended effects — the speed of mind swelling was 12.5% for sufferers on the medicine, versus 1.7% within the placebo group.
Related outcomes had been unveiled the next yr for a second drug, donanemab.
A briefing paper printed by NHS England in 2024 confirmed that the variety of sufferers eligible for illness modifying remedy was estimated to be between 50,000 and 280,000.
Charities referred to as for the well being service to arrange for a rollout by boosting analysis charges and making certain extra folks can entry the checks wanted to verify a particular analysis.
The Medicines and Healthcare merchandise Regulatory Company gave the inexperienced mild to lecanemab in August 2024, deciding it was protected and efficient to be used within the UK.
However the hopes of 1000’s of potential sufferers had been instantly dashed when, in a uncommon coordinated transfer, the Nationwide Institute of Well being and Care Excellence (NICE) introduced concurrently that it could not be recommending the drug to be used on the NHS.
It stated the medicine slowed development of the illness by between 4 and 6 months, a profit dominated “too small to justify the fee”.
NHS drug pricing negotiations are confidential however on the time lecanemab was thought to value round £20,000 per affected person per yr within the US. The price of common scans and appointments to observe sufferers was estimated at an extra £19,000.
A million folks within the UK are regarded as dwelling with dementia. (Picture: Getty)
Dementia charities and campaigners had been upset. David Thomas, Alzheimer’s Analysis UK’s head of coverage, predicted the ruling would put the drug out of attain for “all however probably the most rich”.
The identical ruling — licensed, however not accepted for the NHS — adopted for donanemab in October 2024.
At present, the small variety of UK sufferers who’re accessing the medicine are both paying privately or enrolled in a scientific trial. No dependable information exists on the quantity however it’s thought to fall within the low tons of.
The Categorical revealed final month that sufferers are additionally travelling from overseas to entry personal prescriptions in London. Lykke Vestergaard Kastbjerg, 42, who makes the journey from Denmark each month along with her father Niels, 73, stated: “It’s my dad’s life, it doesn’t have a worth for me.”
It might be simple to rage on the injustice of this case. When a drug exists that may gradual a illness as devastating as Alzheimer’s, why can the NHS and authorities not discover a method to supply entry, even to a restricted group?
Nonetheless, we should do not forget that each drug funding choice has penalties. I attended a medical convention in Berlin a few years in the past the place there was a thought-provoking discuss on remedy entry campaigns.
Heartbreaking appeals from sufferers determined to attempt the most recent life-changing remedy will be extraordinarily highly effective and compelling, the speaker stated. However funding a drug for one particular person would possibly successfully imply taking a remedy away from another person. The NHS has a finite pot of money, which is why NICE should be the arbitrator of value effectiveness.
Many consultants who had been bitterly upset on the rejection of the 2 dementia medicine would additionally acknowledge that these had been most likely the appropriate choices.
NICE introduced final month that it could evaluate components of its assessments following appeals from the producers. It admitted, for instance, that it didn’t absolutely take into consideration the affect of dementia on unpaid carers.
However this evaluate is just not anticipated to overturn the general ruling on both remedy. NICE has stated the medicine had been estimated to value 5 to 6 instances greater than the brink it could usually suggest. New thresholds now apply that are even increased.
138 Alzheimer’s medicine had been in scientific trials in early 2025. (Picture: Getty)
For the medicine to be accepted, one aspect of the equation would want to shift dramatically; the confirmed profit should be better or the value decrease.
Nonetheless, there may be hope on the horizon. New trials are investigating whether or not combining one in every of these medicine with these concentrating on different mind pathologies, reminiscent of Lewy our bodies or tau tangles, produces a greater outcome.
And a second era of anti-Alzheimer’s medicine is already in improvement. One instance is remternetug, thought-about the observe as much as donanemab and made by the identical producer, Eli Lilly.
It’s being examined in a part three trial with greater than 1,600 sufferers aged 60-85, which is anticipated to finish this yr. It may be given through a subcutaneous injection just like an insulin pen, quite than the intravenous technique utilized in earlier trials, which may carry down administration prices.
A serious unbiased evaluate by the London-based world organisation Cochrane is anticipated to publish its evaluation of the anti-amyloid medicine panorama subsequent week.
Cochrane Opinions, which analyse all of the high-quality proof on a subject, are internationally recognised because the gold normal of evidence-based drugs. They are often extremely influential and NICE committees usually use these rigorous reviews to make scientific suggestions.
Different medicine in improvement usually are not concentrating on amyloid in any respect, as an alternative specializing in different poisonous proteins related to Alzheimer’s reminiscent of tau.
Charities have rightly continued to name for the NHS and ministers to arrange to roll out disease-modifying therapies. Round a million individuals are dwelling with dementia within the UK however one in three don’t have any analysis, creating an instantaneous barrier.
Professor Fiona Carragher, Alzheimer’s Society’s chief coverage and analysis officer, has warned that “the science is flying however the system is failing”.
She stated final summer time: “Even when donanemab and lecanemab had been made out there on the NHS tomorrow, too many sufferers wouldn’t be capable to entry them as a result of the well being system isn’t able to ship them.”
Lecanemab and donanemab is probably not the primary therapies rolled out on the NHS, however they had been breakthrough medicine — the primary to maneuver past simply masking signs to really sort out the underlying illness pathology.
Being a step nearer to a extensively out there NHS remedy should still appear to be a step too far-off for the 1000’s of households affected by dementia within the UK.
Nonetheless, a first-in-class drugs isn’t the very best and there’s a sturdy world pipeline of medication in improvement. An annual report by famend US neurologist Dr Jeffrey Cummings discovered there have been 138 Alzheimer’s medicine being assessed in 182 scientific trials in January 2025, up from 127 medicine in 164 trials the earlier yr.
It might take a little bit longer than first hoped when that breakthrough was celebrated in 2022, however there isn’t a doubt that we’re transferring in the appropriate path.
Leave a Reply